Navigation Links
Takeda's New Investigational Drug Vedolizumab is Granted Priority Review Status by U.S. Food and Drug Administration for Ulcerative Colitis
Date:9/4/2013

only, which includes the colon and the rectum. The most common symptoms of UC include abdominal discomfort and blood or pus in diarrhea. There is no known cause for CD or UC, although many researchers believe that the interaction between genes, the body's immune system, and environmental factors may play a role. The aim of CD and UC treatments is to induce and maintain remission, or achieve extended periods of time when patients do not experience symptoms.

About vedolizumab
Vedolizumab, under development for the treatment of CD and UC, is a humanized monoclonal antibody that specifically antagonizes the alpha4beta7 integrin, inhibiting the binding of alpha4beta7 to intestinal mucosal addressin cell adhesion molecule 1 (MAdCAM-1). MAdCAM-1 is preferentially expressed on blood vessels and lymph nodes of the gastrointestinal tract. The alpha4beta7 integrin is expressed on a subset of circulating white blood cells. These cells have been shown to play a role in mediating the inflammatory process in CD and UC. 

About Takeda Pharmaceuticals U.S.A., Inc.
Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine.

The company has a commercial presence covering around 70 countries, with particular strength in Asia, North America, Europe and fast-growing emerging markets including Latin America, Russia-CIS and China. Takeda is ranked 12th by global Rx sales, 14th in the BRIC countries and 18th in Europe. Areas of focus include cardiovascular and metabolic, oncology, respiratory and immunology, central nervou
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohns Disease
2. FDA Grants Orphan Drug Status To Eisais Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
3. New Data for Abbotts Investigational High Sensitive Troponin Test Shows It May Help Doctors Predict Heart Attack Risk
4. Grifols Implements Its First Automated Inventory Management Carousel System for Investigational Pharmacies at Emory University
5. Signum Dermalogix Investigational New Drug (IND) Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea
6. Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300
7. Phase III study finds investigational agent empagliflozin significantly reduced blood glucose in adults with type 2 diabetes and impaired kidney function
8. Phase III data show investigational compound empagliflozin significantly reduced blood glucose in adults with type 2 diabetes
9. Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
10. Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
11. Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohns Disease and Ulcerative Colitis in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... OSAKA, Japan , Aug. 28, 2014 /PRNewswire/ ... completion of the post-marketing commitment and submissions of ... authorities including the United States ... European Medicines Agency (EMA) and the Japanese Ministry ... Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for ...
(Date:8/28/2014)... 2014  In anticipation of the upcoming MEDevice San ... for the first time. Industry Overview: Medtech & Life ... a snapshot of San Diego,s critical ... the latest employment statistics to current venture capital investment trends, ... such a vital part of the global medical ...
(Date:8/28/2014)... /PRNewswire-iReach/ -- Academy Leadership, an elite leadership training firm ... a case study highlighting one manager,s experience ... In September and October 2014, Academy Leadership affiliates are ... , Indianapolis , Salt Lake City , ... http://photos.prnewswire.com/prnh/20140828/140814 Leadership training for managers ...
Breaking Medicine Technology:Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 2Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 3Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 4Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 5Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 6New Infographic Published - Overview of Medtech & Life Sciences Industry in San Diego 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 3Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 4Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 5
... Aug. 1, 2011 eResearchTechnology, Inc. (ERT), (Nasdaq: ... of services and customizable medical devices to biopharmaceutical ... cardiac safety and respiratory efficacy services in drug ... ended June 30, 2011.  Unless otherwise noted, all ...
... 2011 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) ... results after the NASDAQ Global Select Market closes on Tuesday, ... and Chief Executive Officer, will host a conference call and ... to discuss the financial results for the second quarter 2011 ...
Cached Medicine Technology:ERT Reports Second Quarter 2011 Operating Results 2ERT Reports Second Quarter 2011 Operating Results 3ERT Reports Second Quarter 2011 Operating Results 4ERT Reports Second Quarter 2011 Operating Results 5ERT Reports Second Quarter 2011 Operating Results 6ERT Reports Second Quarter 2011 Operating Results 7ERT Reports Second Quarter 2011 Operating Results 8ERT Reports Second Quarter 2011 Operating Results 9ERT Reports Second Quarter 2011 Operating Results 10ERT Reports Second Quarter 2011 Operating Results 11ERT Reports Second Quarter 2011 Operating Results 12ERT Reports Second Quarter 2011 Operating Results 13Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9 2Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9 3
(Date:8/29/2014)... 29, 2014 For the fifth year ... Foundation) will be observing September 26th as Mesothelioma Awareness ... in New York. , Members of the community ... . The Foundation will be providing t-shirts and signs ... mesothelioma community members have received attention from Al ...
(Date:8/29/2014)... PreDiabetes Centers , the country’s leading prediabetes treatment company, ... a 20% discount off orders of $100 or more at ... shop, beginning September 1. , Keeping your body in ... chilly fall season. , Autumn’s cooler, cozier weather often invites ... the healthy salads and opt for creamy soups, hearty casseroles ...
(Date:8/29/2014)... Innovations Television, produced by DMG Productions, announced ... Innovations, focusing on health and elderly care, slated to air ... of Americans over 65 will nearly double by 2030, expanding ... 2030, for a total of 72 million people. Though many ... at least one chronic condition and use healthcare services more ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Scientists from ... idea that progression-free survival correlates with overall survival of ... the new research. Click here to read it ... The Netherlands studied the cases of 523 mesothelioma ... studies. , “PFSR-18 [progression-free survival at 18 weeks ...
(Date:8/29/2014)... Beach, VA (PRWEB) August 29, 2014 ... the top ten tools for online teaching, as well ... for Best Course or Learning Management System, announced that ... Matt Contento, participated in the ALS Ice Bucket Challenge ... and challenge Paul Sanders, Edvance360 Co-Founder. , “We know ...
Breaking Medicine News(10 mins):Health News:Organization to Raise Awareness of Mesothelioma on the Today Show 2Health News:PreDiabetes Centers Online Store Launches Fall Savings Event 2Health News:Innovations with Ed Begley, Jr., Seeking Content for Upcoming Series on Health and Elder Care 2Health News:European Study Says Disease Progression Predicts Mesothelioma Survival Better Than Treatment Response, According to Surviving Mesothelioma 2Health News:Edvance360 Participates In the ALS Ice Bucket Challenge (#ALSicebucketchallenge) 2
... The Brain Tumor Foundation Pays Tribute to Legendary Yankee Bobby,Murcer, ... (BTF),mourns the passing of Yankees icon, Bobby Murcer. His talent ... -- and deeply missed., "If I can save lives, ... the BTF team as an advocate and spokesperson for The ...
... July 14 Millions of lives are at,stake today as ... and,malaria legislation (S. 2731). The debate on the Senate floor ... chance for the bill to be,approved this year., President ... and it,enjoys broad support, including from Senators McCain and Obama ...
... nurse call solutions to thousands of resellers, ... Systems USA, Inc. is,pleased to announce it has ... to offer IgeaCare products and services to its ... e-call and nurse call solution that integrates with ...
... Cooperative of American,Physicians, Inc. (CAP) today announced that ... the 10,000 member level truly represents a milestone ... physicians who founded,CAP more than 30 years ago ... could find a way to manage the escalating ...
... Mass. - In the past 10 years, researchers in ... are associated with areas where human chromosomes break. ... replication causes chromosomal breaking. But why does DNA replication ... the July 14 issue of "Proceedings of the National ...
... friends or stores selling cigarettes make the habit more likely, ... who can get their hands easily on cigarettes -- say ... end up with a regular smoking habit, a new study ... care professionals help kids quit before they even ...
Cached Medicine News:Health News:'If I Can Save Lives, I'm in.' 2Health News:Senator Vitter Threatens Crucial AIDS Bill 2Health News:IgeaCare Systems USA, Inc. enters distribution agreement with Jenne Distributors, Inc. 2Health News:IgeaCare Systems USA, Inc. enters distribution agreement with Jenne Distributors, Inc. 3Health News:Cooperative of American Physicians Membership Tops 10,000 2Health News:Tufts researchers discover link between DNA palindromes and disease 2Health News:Access Is Key to Kids' Decision to Smoke 2
... delivers higher magnification for advanced surgical procedures. ... even at the highest magnification. 3.5x, 4.5x ... precise color rendition is ideal for surgical ... coating produce a superior image. The compact ...
... Advantage delivers higher magnification for advanced surgical ... image, even at the highest magnification. 3.5x, ... and precise color rendition is ideal for ... anti-reflective coating produce a superior image. The ...
... up of doublet objective and high power ... and 3.0x. The true benefit of this ... maintaining focal clarity is made possible due ... ultra lightweight aluminum bar and individual interpupillary ...
... Galilean loupes are ideal for general ... magnification and a large field of ... laser aligned, lightweight and comfortable to ... distance and superior depth of focus ...
Medicine Products: